3-(acetylsulfanyl)-3-phenylpropanoic acid | 51550-47-1

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 苯丙酸
• 英文名称: 3-(acetylsulfanyl)-3-phenylpropanoic acid
• 英文别名: 3-(acetylthio)-3-phenylpropanoic acid；3-acetylsulfanyl-3-phenyl-propionic acid；3-Acetylmercapto-3-phenyl-propionsaeure；I(2)-(Acetylthio)benzenepropanoic acid；3-acetylsulfanyl-3-phenylpropanoic acid
• CAS: 51550-47-1
• 化学式: C₁₁H₁₂O₃S
• 分子量: 224.28
• InChiKey: PGQPCPFNHSITJO-UHFFFAOYSA-N

物化性质

• 熔点：
  95-96 °C
• 沸点：
  355.1±35.0 °C(Predicted)
• 密度：
  1.258±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  15
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.27
• 拓扑面积：
  79.7
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  3-(acetylsulfanyl)-3-phenylpropanoic acid 在 ammonium hydroxide 、 三乙胺 作用下， 以 二氯甲烷 为溶剂， 反应 2.5h， 生成 反-肉桂酰胺
  参考文献：
  名称：

  由Alk-2-enamides方便地合成各种取代的高牛磺酸

  摘要：

  通过将硫代乙酸迈克尔加成至alk-2-enamides 3（→ 4），然后还原LiAlH 4（→ 5），可以容易地以令人满意的令人满意的产率合成各种取代的高牛磺酸（= 3-氨基丙烷-1-磺酸）6）和过甲酸氧化（方案1）。“的结构的抗”二取代的高牛磺酸“反‘ - 6H从3-（乙酰硫基）链烷酰胺（=推导S- （3-氨基-1,2-二甲基-3-氧代丙基）硫代乙酸酯）’抗- ” 4H形成于迈克尔此外，经鉴定通过所述Karplus组方程分析，并利用X射线衍射分析证实。当前路线是合成多样取代homotaurines，包括1-，2-，和一种有效的方法Ñ单取代的，以及1,2-，1，Ñ - ，2，Ñ - ，和Ñ，Ñ二取代homotaurines （表）。

  DOI：

  10.1002/hlca.201200547
• 作为产物：
  描述：

  肉桂酸 在 氢溴酸 作用下， 反应 8.0h， 生成 3-(acetylsulfanyl)-3-phenylpropanoic acid
  参考文献：
  名称：

  钌（II）-芳烃硫代羧酸盐：对侵袭性乳腺癌细胞有选择性的细胞毒性的稳定二聚体的鉴定。

  摘要：

  RuII-芳烃配合物为新型抗癌药物提供了多功能支架。合成并表征了七个新的RuII-芳烃-硫代羧酰二聚体。三种复合物（2a，b和5）在MDA-MB-231（人类浸润性乳腺癌）细胞中显示出有希望的抗增殖活性，并在一组15种癌性和非癌性细胞系中进行了进一步测试。复合物5在MDA-MB-231细胞中表现出中等但显着的选择性活性（IC50 = 39±4μmRu）。实时增殖研究表明5诱导了MDA-MB-231细胞凋亡，但对A549（人肺癌，上皮）细胞无影响。相比之下，2 a和b在这两种细胞系中均显示出中等的抗增殖活性，但没有凋亡。侵袭性细胞的选择性细胞毒性为5，

  DOI：

  10.1002/cbic.201900676

文献信息

• Ethane-1,2-diaminium bis[(2R)-2-bromo-3-phenylpropanoate], processes for its preparation and its use
  申请人：——

  公开号：US20040010039A1

  公开（公告）日：2004-01-15

  The present invention relates to ethane-1,2-diaminium bis[(2R)-2-bromo-3-phenyl-propanoate], the preparation of ethane-1,2-diaminium bis[(2R)-2-bromo-3-phenyl-propanoate] from (2R)-2-bromo-3-phenylpropionic acid and ethylenediamine in 2-propanol, and the use of ethane-1,2-diaminium bis[(2R)-2-bromo-3-phenyl-propanoate] for the preparation of ACE/NEP inhibitors.

  本发明涉及乙烷-1,2-二氨基双[(2R)-2-溴-3-苯基丙酸酯]，从(2R)-2-溴-3-苯基丙酸和乙二胺在2-丙醇中制备乙烷-1,2-二氨基双[(2R)-2-溴-3-苯基丙酸酯]，以及利用乙烷-1,2-二氨基双[(2R)-2-溴-3-苯基丙酸酯]制备ACE/NEP抑制剂。
• Dedicated Asthma Center Improves the Quality of Care and Resource Utilization for Pediatric Asthma: A Multicenter Study
  作者：David S. Battleman、Mark A. Callahan、Steven Silber、Cynthia I. Mun∼oz、Lucia Santiago、Joseph Abularrage、Hadi Jabbar

  DOI：10.1111/j.1553-2712.2001.tb00189.x

  日期：2001.7

  Objectives: To determine the relative effectiveness of pediatric asthma care among patients treated by a dedicated asthma center (AC) vs children who use the emergency department (ED) as a site of primary asthma care. Methods: A retrospective case—control design was used. A random sample of AC cases was selected from a designated comprehensive AC over a 12‐month period. Concurrent ED control patients were identified from all cases of pediatric asthma from five urban hospitals based on two or more ED visits. Cases and controls were matched (1:2) based on age and National Heart, Lung, and Blood Institute (NHLBI) asthma severity of illness classification. A telephone survey was administered to the caregivers of all enrolled patients in the study sample. Results: Four elements of pediatric asthma care were examined: quality, access, hospital utilization, and functional impact of disease. Demographic data were similar between the ED cases and the AC controls. In terms of quality of care, the AC patients were more likely to use maintenance antiinflammatory medications, 60.2% vs 22.5% (OR = 5.3; 95% CI = 2.9 to 9.7) and more likely to be taking medications at school, 71.4% vs 48.1% (OR = 2.7; 95% CI = 1.5 to 4.7). In terms of access to care, the AC families were more likely to have a physician to call to assist with outpatient management, 98.2% vs 65.0% (OR = 25.3; 95% CI = 9.0 to 76.9). Frequent ED utilization (≥ 1 visit/month) was less likely in the AC patients, 9.2% vs 22.0% (OR = 0.35; 95% CI = 0.16 to 0.79) and school absenteeism was lower as well (9.5 ± 6.7 days vs 16.6 ± 10.3, p < 0.001). Additionally, the caregivers of the AC patients missed fewer workdays (4.7 ± 2.8 vs 7.4 ± 4.1; p = 0.03). Conclusions: Significant disparities in quality, access, resource utilization, and functional impact exist between AC and ED patients. Emergency physicians have a unique opportunity to improve the public health by directing ED patients toward pediatric AC treatment.

  **目标:** 确定儿童哮喘治疗在由专门哮喘中心(AC)治疗的患者与将急诊科(ED)作为主要哮喘治疗场所的儿童之间的相对疗效。 **方法:** 使用回顾性病例对照设计。从指定的综合性哮喘中心随机选择AC病例，时间跨度为12个月。对照组ED患者根据两次或以上的ED就诊次数从五所城市医院的所有儿科哮喘病例中确定。病例和对照组根据年龄和美国国立心肺血液研究所(NHLBI)哮喘严重程度分类以1:2的比例进行匹配。向研究样本中所有入组患者的看护者进行了电话调查。 **结果:** 检查了儿童哮喘治疗的四个要素:质量、可及性、住院利用和疾病的功能影响。ED病例和AC对照组的人口统计数据相似。在治疗质量方面，AC患者更有可能使用维持性抗炎药物，60.2% vs 22.5% (OR = 5.3; 95% CI = 2.9 至 9.7)，并且更有可能在学校服药，71.4% vs 48.1% (OR = 2.7; 95% CI = 1.5 至 4.7)。在治疗可及性方面，AC家庭更有可能有一个可以联系的医生来协助门诊管理，98.2% vs 65.0% (OR = 25.3; 95% CI = 9.0 至 76.9)。频繁的ED利用(≥ 1 次/月)在AC患者中不太可能，9.2% vs 22.0% (OR = 0.35; 95% CI = 0.16 至 0.79)，缺课率也较低(9.5 ± 6.7 天 vs 16.6 ± 10.3 天, p < 0.001)。此外，AC患者看护者缺工时间也较少(4.7 ± 2.8 vs 7.4 ± 4.1 天; p = 0.03)。 **结论:** 在质量、可及性、资源利用和疾病影响方面，AC和ED患者之间存在显著差异。急诊医生有独特的机会通过将ED患者引导至儿科哮喘中心治疗来改善公共健康。
• Potential Radiation Protective Agents V. Synthetic Approaches to 2-Aryl-2-Mercaptoethylamines
  作者：Beng-Thong Ho、Walter C. McCarthy

  DOI：10.1002/jps.2600560524

  日期：1967.5

  Abstract β-Acetthiohydrocinnamoyl azide, through the Curtius degradation, gave 2-mercapto-2-phenylethylamine hydrochloride in low yield. Following the nitro-thiolacetate route to 2-aryl-2-mercaptoethylamines, two acetoxy-substituted β -nitrostyrenes were found to undergo an anomalous reaction with thiolacetic acid involving reduction of the nitro group, formation of elemental sulfur, and the isolation

  摘要β-乙硫基氢肉桂酰基叠氮化物经Curtius降解，低收率得到2-巯基-2-苯基乙胺盐酸盐。继硝基硫醇乙酸盐途径生成2-芳基-2-巯基乙胺后，发现两个乙酰氧基取代的β-硝基苯乙烯与硫代乙酸发生异常反应，包括硝基还原，元素硫的形成以及含比起始原料多四个乙酰基。
• Dynamic resolution of isomers and resolved isomers
  申请人：——

  公开号：US20020111512A1

  公开（公告）日：2002-08-15

  Provided is a dynamic resolution method of enriching a desired isomer of an alpha-substituted carboxylic acid relative to an undesired isomer, the method comprising: (a) in a solvent, contacting the alpha-substituted carboxylic acid, wherein the alpha substitution is with a leaving group and wherein the alpha carbon is chiral, with a homochiral amine to form a salt that is partially insoluble under selected reaction conditions, wherein the homochiral amine is selected so that the solubility of the amine salt of the undesired alpha-substituted carboxylic acid is greater than that of the amine salt of the desired alpha-substituted carboxylic acid under the selected reaction conditions; (b) reacting under the selected reaction conditions the salt with a nucleophile, wherein the reacting is effective in producing a net increase in the less soluble amine salt of the alpha-substituted carboxylic acid, and wherein the selected conditions are selected to (i) promote nucleophilic substitution of the nucleophile and the leaving group or (ii) to produce the increase in the less soluble amine salt in the absence of a strong base; and (c) maintaining the reaction for a period of time effective to increase the amount of the desired alpha-substituted carboxylic acid isomer.

  提供一种动态分辨方法，用于富集所需的α-取代羧酸同分异构体相对于不需要的同分异构体，该方法包括：（a）在溶剂中，将α-取代羧酸与手性同构胺接触，其中α取代基带有离去基团，α碳是手性的，形成部分不溶于所选反应条件下的盐，其中所选的手性同构胺被选择为在所选反应条件下，不需要的α-取代羧酸胺盐的溶解度大于所需的α-取代羧酸胺盐的溶解度；（b）在所选的反应条件下，用亲核试剂反应所述盐，反应有效地产生较不溶的α-取代羧酸胺盐的净增加，所选条件被选择为（i）促进亲核试剂和离去基团的亲核取代或（ii）在没有强碱的情况下产生较不溶的胺盐的增加；（c）维持反应一段有效时间，以增加所需的α-取代羧酸同分异构体的数量。
• PROCESS FOR THE PREPARATION OF (R)-2-BROMO-3-PHENYL-PROPIONIC ACID
  申请人：DSM N.V.

  公开号：EP1272452A2

  公开（公告）日：2003-01-08